淋巴细胞性瘢痕性脱发的序贯小分子治疗:多中心前瞻性队列初步研究
本研究为多中心前瞻性队列初步研究,纳入33例组织病理学确诊的活动性淋巴细胞性瘢痕性脱发(LCA)成人患者,评估预设的三阶段序贯小分子治疗方案。31例完成方案,基线LPPAI从5.65±1.45显著降至III阶段0.75±0.27(改善率85.5%,P<.001),93.5%患者获显著改善,仅3例轻度不良事件。
要点
- 三阶段序贯方案(托法替布+克立硼罗→阿普米司特+克立硼罗→克立硼罗单用)可显著降低LPPAI。
- 31例完成者中93.5%达显著改善,仅3例轻度不良事件,耐受性良好。
- 样本量小、无对照组、随访短,结论需更大规模对照研究验证。
核心结论
- 在该患者队列中,三阶段序贯小分子方案耐受性良好,为活动性LCA提供了有前景的治疗选择。
研究设计与样本
- 多中心前瞻性队列初步研究,在中国3家三级中心纳入33例组织病理学确诊的活动性LCA成人患者。
- 方案分三阶段:I阶段口服托法替布+外用克立硼罗,II阶段口服阿普米司特+外用克立硼罗,III阶段单用外用克立硼罗。
- 主要结局为纵向LPPAI及其改善率(ILPPAIS%)。
主要发现
- 33例中31例完成方案。
- 基线LPPAI为5.65±1.45,III阶段降至0.75±0.27(ILPPAIS% 85.5%,P<.001)。
- 93.5%患者达显著改善,仅发生3例轻度不良事件。
临床怎么用
- 对活动性LCA成人患者,可考虑三阶段序贯小分子方案作为治疗选择,但需结合个体情况并监测不良事件。
局限性
- 样本量小。
- 缺乏对照组。
- 随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lymphocytic cicatricial alopecia (LCA) is a rare disorder causing irreversible hair follicle stem cell damage, with limited evidence supporting systemic treatments. OBJECTIVE: To assess the efficacy and safety of a predefined three-stage sequential small-molecule therapy for active LCA. METHODS: This multicenter prospective cohort pilot study enrolled adults with histopathologically confirmed active LCA at 3 Chinese tertiary centers. The regimen included oral Tofacitinib + topical Crisaborole (Stage I), oral Apremilast + topical Crisaborole (Stage II), and topical Crisaborole alone (Stage III). Primary outcomes were longitudinal Lichen Planopilaris Activity Index (LPPAI) and its improvement rate (ILPPAIS%). RESULTS: Of 33 patients, 31 completed the regimen. Baseline LPPAI (5.65 ± 1.45) decreased significantly to 0.75 ± 0.27 (ILPPAIS% 85.5%, P < .001) at Stage III; 93.5% achieved marked improvement with only 3 mild adverse events. LIMITATIONS: Small sample size, lack of control group, and short follow-up. CONCLUSION: In this patient cohort, three-stage sequential regimen was well tolerated and offers a promising treatment option for active LCA.
引用
- Li Y, Shao G, Tao Q, et al. Sequential small-molecule therapy for lymphocytic cicatricial alopecia: A multicenter prospective cohort pilot study. J Am Acad Dermatol. 2026. PMID: 41812983. doi:10.1016/j.jaad.2026.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。